Advanced Renal Cell Carcinoma (RCC) treatment
搜索文档
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Businesswire· 2026-02-28 23:00
核心观点 - 公司宣布其药物WELIREG联合LENVIMA在特定经治肾细胞癌患者的三期临床试验中取得积极结果 与对照药物Cabozantinib相比 将疾病进展或死亡风险降低了30% [1] 临床试验结果 - WELIREG联合LENVIMA治疗方案在特定先前接受过治疗的肾细胞癌患者中显示出显著疗效 [1] - 与活性对照药物Cabozantinib相比 该联合疗法使疾病进展或死亡风险降低了30% [1]
